Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)

Prevention
People at high risk for prostate cancer due to an inherited mutation

Study Contact Information:

For additional information, please contact:

Olympia Price by phone: 857-238-3838
or by email: [email protected]

About the Study

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

What the Study Involves

Two groups of patients will be enrolled in this study:

One group will enroll people who have an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53
The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for prostate cancer.

Both study groups will receive the same cancer screening tests:

physical exam (digital rectal exam)
prostate-specific antigen (PSA) test
MRI of the prostate.

Study participants will be followed for up to 20 years.

Study Location

Massachusetts

Boston, MA
Massachusetts General Hospital
Lead Researcher: Keyan Salari, MD, PhD
Study coordinator: Olympia Price: 857-238-3838 or [email protected]

This Study is Open To:

Men age 35-74 years old who meet the following criteria may be eligible:

No prior diagnosis of prostate cancer
Meets either group 1 or group 2 criteria:
- Group 1: has an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53.
- Group 2: has a strong family history suggestive of high genetic risk for prostate cancer but with no inherited genetic mutation.

This Study is Not Open To:

Men are not eligible to participate if they:

have had a prior diagnosis or treatment of prostate cancer
are not able to undergo a prostate MRI or receive the MRI contrast agent

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.